AU2009215168A1 - Fish assay for EML4 and ALK fusion in lung cancer - Google Patents

Fish assay for EML4 and ALK fusion in lung cancer Download PDF

Info

Publication number
AU2009215168A1
AU2009215168A1 AU2009215168A AU2009215168A AU2009215168A1 AU 2009215168 A1 AU2009215168 A1 AU 2009215168A1 AU 2009215168 A AU2009215168 A AU 2009215168A AU 2009215168 A AU2009215168 A AU 2009215168A AU 2009215168 A1 AU2009215168 A1 AU 2009215168A1
Authority
AU
Australia
Prior art keywords
alk
inversion
probe
eml4
chromosome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009215168A
Other languages
English (en)
Inventor
Pasi Janne
Charles Lee
Carly Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Dana Farber Cancer Institute Inc
Original Assignee
Brigham and Womens Hospital Inc
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Dana Farber Cancer Institute Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU2009215168A1 publication Critical patent/AU2009215168A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2009215168A 2008-02-12 2009-02-12 Fish assay for EML4 and ALK fusion in lung cancer Abandoned AU2009215168A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6542208P 2008-02-12 2008-02-12
US61/065,422 2008-02-12
PCT/US2009/000879 WO2009102446A2 (en) 2008-02-12 2009-02-12 Fish assay for eml4 and alk fusion in lung cancer

Publications (1)

Publication Number Publication Date
AU2009215168A1 true AU2009215168A1 (en) 2009-08-20

Family

ID=40957428

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009215168A Abandoned AU2009215168A1 (en) 2008-02-12 2009-02-12 Fish assay for EML4 and ALK fusion in lung cancer

Country Status (6)

Country Link
US (1) US20110110923A1 (enExample)
EP (1) EP2255190A4 (enExample)
JP (1) JP2011511949A (enExample)
AU (1) AU2009215168A1 (enExample)
CA (1) CA2715380A1 (enExample)
WO (1) WO2009102446A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
ES2561406T3 (es) 2006-04-14 2016-02-26 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP3546596B1 (en) 2009-05-26 2022-05-11 Quest Diagnostics Investments Incorporated Use of a kit for detecting gene dysregulations
US8546552B2 (en) 2009-12-23 2013-10-01 Quest Diagnostics Investments Incorporated TMPRSS2 for the diagnosis of prostate disease
AR080913A1 (es) * 2010-04-16 2012-05-16 Response Genetics Cebadores, sondas, metodos y conjuntos de elementos para la deteccion de variantes de eml4- alk
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
EP2670867B1 (en) * 2011-02-04 2017-11-01 The Trustees Of The University Of Pennsylvania A method for detecting chromosome structure and gene expression simultaneously in single cells
DE102011100242A1 (de) * 2011-05-02 2012-11-08 Zytovision Gmbh Verfahren zur Detektion von Chromosomenaberration
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
EP2714038A1 (en) 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
CA3113672A1 (en) 2011-07-01 2013-01-10 Htg Molecular Diagnostics, Inc. Methods of detecting gene fusions
EP2729144A2 (en) * 2011-07-07 2014-05-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
DK2838998T3 (en) 2012-04-18 2018-01-15 Cell Signaling Technology Inc EGFR AND ROS1 IN CANCER
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2013170182A1 (en) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
RU2509153C1 (ru) * 2012-11-28 2014-03-10 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) Способ анализа транслокаций eml4-alk, ассоциированных с чувствительностью рака легкого к противоопухолевой таргетной терапии
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EA033304B1 (ru) 2014-02-04 2019-09-30 Астеллас Фарма Инк. Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
JP2018504446A (ja) 2015-02-09 2018-02-15 シンタ ファーマシューティカルズ コーポレーション がんを処置するためのｈｓｐ９０阻害剤およびｐｄ−１阻害剤の組み合わせ治療
CN105368962A (zh) * 2015-12-18 2016-03-02 河南赛诺特生物技术有限公司 肺癌alk基因重排快速检测荧光探针及制备方法
CN105543353A (zh) * 2015-12-30 2016-05-04 广州安必平医药科技股份有限公司 Alk基因和eml4基因检测探针及其制备方法和试剂盒
JP6728503B2 (ja) 2017-02-24 2020-07-22 テグ−キョンプク メディカル イノベーション ファウンデーション 血液脳関門を通過することができる化合物を有効成分として含有する脳腫瘍の予防または治療用薬学的組成物
CN108998503B (zh) * 2018-08-17 2022-04-05 中山康源基因技术科技有限公司 一种Oligo探针及其制备方法与应用
CN110066876A (zh) * 2019-06-06 2019-07-30 徐州医科大学 一种用于癌症诊断的分子标志物
AU2019460208A1 (en) * 2019-08-05 2022-03-17 Genex Health Co., Ltd Method for culturing primary cells of lung cancer solid tumor and primary tumor cells of lung cancer pleural effusion, and supporting reagent
JP7385191B2 (ja) * 2019-08-30 2023-11-22 学校法人同志社 Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬
KR102449858B1 (ko) * 2021-07-08 2022-09-30 가톨릭대학교 산학협력단 암 세포 판정을 위한 핵이미지 선별 장치 및 핵이미지 선별 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756696A (en) * 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5447841A (en) * 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US6280929B1 (en) * 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US6344315B1 (en) * 1986-01-16 2002-02-05 The Regents Of The University Of California Chromosome-specific staining to detect genetic rearrangements associated with chromosome 3 and/or chromosome 17
AU647741B2 (en) * 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
US5491224A (en) * 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US7288529B2 (en) * 2003-04-24 2007-10-30 New York University ALK protein tyrosine kinase, cells and methods embodying and using same
US8062897B2 (en) * 2003-07-21 2011-11-22 Aureon Laboratories, Inc. Diagnostic histopathology using multiplex gene expression FISH
JP3884462B2 (ja) * 2005-10-14 2007-02-21 株式会社ファースト 高速画像探索方法
ES2561406T3 (es) * 2006-04-14 2016-02-26 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
EP1914240B1 (en) * 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
JP5562640B2 (ja) * 2007-04-13 2014-07-30 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ

Also Published As

Publication number Publication date
JP2011511949A (ja) 2011-04-14
CA2715380A1 (en) 2009-08-20
WO2009102446A3 (en) 2009-11-26
EP2255190A2 (en) 2010-12-01
EP2255190A4 (en) 2011-05-04
WO2009102446A2 (en) 2009-08-20
US20110110923A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
US20110110923A1 (en) Fish assay for eml4 and alk fusion in lung cancer
Pramanik et al. The human AP-endonuclease 1 (APE1) is a DNA G-quadruplex structure binding protein and regulates KRAS expression in pancreatic ductal adenocarcinoma cells
McDermott et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors
AU2014229505B2 (en) Method for the prognosis and treatment of cancer metastasis
EP3825692B1 (en) Method for the prognosis and treatment of cancer metastasis
Wassef et al. Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis
EP2859120B1 (en) Method for the diagnosis and prognosis of lung cancer metastasis
Guo et al. Characterization of functionally active gene fusions in human papillomavirus related oropharyngeal squamous cell carcinoma
AU2014333513B2 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
EP3690059A1 (en) Fgfr expression and susceptibility to an fgfr inhibitor
US20220023294A1 (en) Synthetic lethality and the treatment of cancer
Injinari et al. Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer
Shi et al. Downregulation of MSP58 inhibits growth of human colorectal cancer cells via regulation of the cyclin D1–cyclin‐dependent kinase 4–p21 pathway
Bozhanov et al. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer
Geron et al. Molecular characterization of Wnt pathway and function of β-catenin overexpression in medulloblastoma cell lines
WO2013165320A1 (en) Treating cancer by increasing expression of socs6
Ishihara et al. ITCH is a putative target for a novel 20q11. 22 amplification detected in anaplastic thyroid carcinoma cells by array‐based comparative genomic hybridization
Struve et al. Increased replication stress and R-loop accumulation in EGFRvIII-expressing glioblastoma present new therapeutic opportunities
Tamkovich et al. Circulating DNA in the blood and its application in medical diagnosis
WO2013111668A1 (ja) Kif5b遺伝子とret遺伝子との間の転座を検出するfishアッセイ
WO2022229846A1 (en) Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
Chrysanthakopoulos The Role of Tumor Suppressor Genes in Molecular and Biological Basis of Lung Cancer

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application